Kunkel Lori Anne
SEC CIK 1536368 · EDGAR
BoughtSold
Most active insiders at ELVN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 10% | — | $51.68M |
| 2 | Derynck Mika K | Dir | — | $9.56M |
| 3 | Collins Helen Louise | Chief MEDICAL Off | — | $5.39M |
| 4 | Lyssikatos Joseph P | CSO | — | $4.88M |
| 5 | Patel Anish | COO | — | $1.74M |
| 6 | Hohl Benjamin | CFO | — | $1.60M |
| 7 | Kunkel Lori Anne | Dir | — | $850.3K |
| 8 | Kintz Samuel | Pres AND CEO, Dir | — | $613.6K |
| 9 | Heyman Richard A. | Dir | — | $413.4K |
Transactions 8
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-07-08 17:15 | 2026-07-06 | ELVN | Enliven Therapeutics, Inc. | Kunkel Lori Anne | Dir | S - Sale | $50.49 | -10.0K | 41.9K | -19% | -$504.9K |
| MT | 2026-06-09 16:49 | 2026-06-05 | ELVN | Enliven Therapeutics, Inc. | Kunkel Lori Anne | Dir | S - Sale | $34.54 | -10.0K | 51.9K | -16% | -$345.4K |
| D | 2025-12-19 | 2025-12-17 | ELVN | Enliven Therapeutics, Inc. | Kunkel Lori Anne | Dir | M - OptEx | $1.12 | +16.0K | 30.7K | +108% | +$17.9K |
| D | 2025-12-09 | 2025-12-08 | ORIC | Oric Pharmaceuticals, Inc. | Kunkel Lori Anne | Dir | M - OptEx | $7.90 | +10.0K | 84.2K | +13% | +$79.0K |
| D | 2025-12-05 | 2025-12-04 | ORIC | Oric Pharmaceuticals, Inc. | Kunkel Lori Anne | Dir | M - OptEx | $3.75 | +5,534 | 74.2K | +8% | +$20.8K |
| DM | 2025-03-04 | 2025-03-03 | ORIC | Oric Pharmaceuticals, Inc. | Kunkel Lori Anne | Dir | M - OptEx | $4.85 | +48.2K | 48.2K | New | +$233.5K |
| 2024-07-18 | 2024-07-17 | NRIX | Nurix Therapeutics, Inc. | Kunkel Lori Anne | Dir | G - Gift | $0.00 | -54.0K | 0 | -100% | $0 | |
| D | 2024-06-04 | 2024-06-03 | ORIC | Oric Pharmaceuticals, Inc. | Kunkel Lori Anne | Dir | M - OptEx | $3.75 | +20.5K | 20.5K | New | +$76.9K |
Purchase Sale Sale after option exercise All abbreviations